A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors
Breast Cancer
Ovarian Cancer
Non-small Cell Lung Cancer

Interventions: Drug: NC762

Registration Number: NCT04875806

Lead Sponsor: NextCure, Inc.

Brief Summary: This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 40

Inclusion Criteria

Men and women aged 18 or older.
Willingness to provide written informed consent for the study.
ECOG performance status 0 to 1.
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. Note: There is no limit to the number of prior treatment regimens.
Presence of measurable disease based on RECIST v1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other locoregional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.
Phase 1a Dose Escalation (optional), Phase 1b Safety Expansion, and Phase 2 (mandatory): Willingness to undergo pretreatment and on-treatment tumor biopsies (core or excisional).
Female subjects of childbearing potential (defined as women who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy and are not postmenopausal, defined as ≥ 12 months of amenorrhea) and non-sterilized male subjects of childbearing potential must agree to take appropriate precautions to avoid pregnancy or fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study drug. Females of child-bearing potential must have a negative serum pregnancy test at screening.

Exclusion Criteria

Inability to comprehend or unwilling to sign the ICF.
Laboratory and medical history parameters not within the protocol-defined range.
1. Absolute neutrophil count < 1.5 × 10^9/L.
2. Platelets < 100 × 10^9/L.
3. Hemoglobin < 9 g/dL or < 5.6 mmol/L.
4. Serum creatinine > 1.5 × institutional upper limit of normal (ULN) and measured or calculated creatinine clearance < 50 mL/min for subjects with creatinine levels > 1.5 × institutional ULN.
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 × ULN. With the following exceptions: subjects with documented liver metastases AST and/or ALT ≤ 5 × ULN. Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5 ×ULN.
6. Total bilirubin ≥ 1.5 × ULN.
7. International normalized ratio (INR) or prothrombin time (PT) > 1.5 × ULN; Activated partial thromboplastin time (aPTT) > 1.5 × ULN, except for subjects on anticoagulation.
Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 7 days before the first administration of study drug.
Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:
1. ≤ 14 days for chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy. Subjects must not have had radiation pneumonitis because of a treatment. A 1-week washout is permitted for palliative radiation to non-central nervous system (CNS) disease with medical monitor approval.
2. ≤ 28 days for prior immunotherapy or persistence of active cellular therapy (e.g., chimeric antigen receptor T cell therapy; other cellular therapies must be discussed with the medical monitor to determine eligibility).
3. ≤ 28 days for a prior mAb used for anticancer therapy except for denosumab.
4. ≤ 7 days for immune-suppressive-based treatment for any reason.
5. ≤ 28 days or 5 half-lives, t½, (whichever is longer) before the first dose for all other investigational study drugs or devices. For investigational agents with long half-lives (e.g., > 5 days), enrollment before the fifth t½ requires medical monitor approval.
6. ≤ 14 days for a COVID-19 vaccine. Note: For 2-dose vaccines, subjects must wait at least 14 days after administration of the 2nd dose of the vaccine prior to receiving the first dose of the study drug.
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy and radiation therapy) and/or complications from prior surgical intervention before starting therapy.
Receipt of a live vaccine within 30 days of planned start of study therapy.
Active autoimmune disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
Known active CNS metastases and/or carcinomatous meningitis.
Known concurrent malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
Documented known activating or driver mutations (i.e. EGFR mutations/amplification, BRAF mutations, ALK alterations, etc.) which have not been previously treated with a standard of care targeted therapy.
Subjects with screening QTc interval > 470 milliseconds (corrected by Fridericia) are excluded.
Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate anti-infection treatment.
Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV), unless the hepatitis is considered to be cured.
Known history of HIV (HIV 1 or HIV 2 antibodies).
Known allergy or reaction to any component of study drug or formulation components.
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study treatment.
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
0.5mg/kg NC762	NC762	Subjects received NC762 IV at 0.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
1.5mg/kg NC762	NC762	Subjects received NC762 IV at 1.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
5mg/kg NC762	NC762	Subjects received NC762 IV at 5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
10mg/kg NC762	NC762	Subjects received NC762 IV at 10mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
20mg/kg NC762	NC762	Subjects received NC762 IV at 20mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0	From enrollment through up to 90 days after end of treatment, an average of 1 year	Frequency, duration, and severity of treatment-emergent adverse events (AEs)

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Approximately 1 year	To assess antitumor activity/efficacy by evaluating objective response rate (ORR), defined as the percentage of participants who experienced a complete response (CR; disappearance of all target lesions) or a partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Maximum Serum Concentration (Cmax) of NC762	Days 1, 2, 3, and 8 of Cycles 1 and 5. Each cycle is 14 days.	To evaluate the Maximum Serum Concentration (Cmax) of NC762
Area Under the Curve (AUC) of NC762	Days 1, 2, 3, and 8 of Cycles 1 and 5. Each cycle is 14 days.	To evaluate the Area Under the Curve (AUC) of NC762
Half-life (T1/2) of NC762	Days 1, 2, 3, and 8 of Cycles 1 and 5. Each cycle is 14 days.	To evaluate the Half-life (T1/2) of NC762
Overall Survival (OS)	Approximately 1 year	To evaluate overall survival (OS), defined as the time from the first dose of NC762 to death due to any cause.
Duration of Response (DoR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Approximately 1 year	To assess antitumor activity/efficacy by evaluating duration of response (DoR), defined as the time from the first documented complete response or partial response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 to the first documented progressive disease or death due to any cause, whichever occurs first. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions.
Disease Control Rate (DCR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Approximately 1 year	To assess antitumor activity/efficacy by evaluating disease control rate (DCR), defined as the proportion of participants in whom a documented complete response, partial response, or stable disease is observed as the best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Approximately 1 year	To evaluate progression-free survival (PFS), defined as the time from the first dose of NC762 to the first occurrence of documented progressive disease or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Trial Locations

Locations (8): John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸
Hackensack, New Jersey, United States
Inova Schar Cancer Institute
🇺🇸
Fairfax, Virginia, United States
Carolina BioOncology Institute
🇺🇸
Huntersville, North Carolina, United States
Gettysburg Cancer Center
🇺🇸
Gettysburg, Pennsylvania, United States
UPMC Hillman Cancer Center
🇺🇸
Pittsburgh, Pennsylvania, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Yale Cancer Center
🇺🇸
New Haven, Connecticut, United States
The University of Chicago Medicine and Biological Sciences
🇺🇸
Chicago, Illinois, United States